吡格列酮治疗对2型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响

The Influence of Blood Sugar, Insulin Resistance and Inflammatory Cytokines on Type 2 Diabetes Patients with Metabolic Syndrome Treated by Pioglitazone

目的:探讨吡格列酮治疗对2型糖尿病合并代谢综合征患者血糖、胰岛素抵抗和炎症因子的影响。方法:回顾性分析我院2013年8月-2015年2月收治的96例2型糖尿病合并代谢综合征患者病例资料,根据治疗方法的不同分为观察组和对照组,每组48例,两组患者均给予糖尿病常规基础治疗,在此基础上,观察组患者给予吡格列酮治疗,治疗3个月。检测治疗前后血糖指标包括空腹血糖(FPG)、餐后2小时血糖(2h PG)以及糖化血糖蛋白(Hb A1c),胰岛素抵抗指标包括空腹胰岛素(FINS)和胰岛素抵抗指数(HOMA-IR)和炎症因子包括超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)。结果:观察组治疗后FPG、2 h PG、Hb A1c分别为(6.19±2.24)mmol/L、(8.30±2.48)mmol/L和(6.01±1.23)%,均显著低于治疗前和对照组治疗后,差异有统计学意义(P<0.05);观察组治疗后FINS和HOMA-IR分别为(6.60±1.92)m IU/L和2.08±1.00,均较治疗前和对照组治疗后显著降低,差异有统计学意义(P<0.05);观察组治疗后hs-CRP、IL-6和TNF-α分别为(6.12±1.67)ng/L、(62.65±10.30)ng/L和(83.16±16.55)ng/L,均较治疗前和对照组治疗后显著降低,差异有统计学意义(P<0.05)。结论:吡格列酮治疗可以显著降低2型糖尿病合并代谢综合征患者血糖水平,改善胰岛素抵抗,降低炎症反应,值得进一步研究。

Objective： To explore the influence of blood sugar, insulin resistance and inflammatory cytokines on type 2 diabetes patients with metabolic syndrome treated by Pioglitazon. Methods： 96 cases type 2 diabetes patients with metabolic syndrome were divided into observation group and control group according to therapeutic method, 48 cases in each group, patients in two groups were given diabetes treatment on a regular basis, and on this basis, the observation group was treated with pioglitazone, treated for 3 months. Detected blood sugar index including fasting plasma glucose（FPG）, blood sugar 2 hours after meal（2h PG） and glycosylated protein（Hb A1c）,blood sugar insulin resistance index including fasting insulin（FINS） and insulin resistance index（HOMA-IR） and inflammation factors including hypersensitive c-reactive protein（hs-CRP） and interleukin 6（IL-6） and tumor necrosis factor alpha（TNF- α） before and after treatment. Results： The levels of FPG, 2h PG, Hb A1 c in observation group after treatment were respectively（6.19 ±2.24）mmol/L,（8.30±2.48）mmol/Land（6.01±1.23）%, they were significantly lower than before treatment and the control group after treatment, the difference was statistically significant（P〈0.05）; The levels of FINS and HOMA-IR in observation group after treatment were respectively（6.60±1.92）m IU/L and 2.08±1.00, they were significantly decreased than before treatment and the control group after treatment, the difference was statistically significant（P〈0.05）; The levels of hs-CRP, IL-6 and TNF-α in observation group after treatment were respectively（6.12±1.67）ng/L,（62.65±10.30）ng/Land（83.16±16.55）ng/L, they were significantly decreased than before treatment and the control group after treatment, the difference was statistically significant（P〈0.05）. Conclusion： Pioglitazone can significantly reduce blood sugar levels and improve insulin resistance, reduce inflammation in type 2 diabetes patients with metabolic syndrome, it deserves further research.